JP2024504632A5 - - Google Patents
Info
- Publication number
- JP2024504632A5 JP2024504632A5 JP2023542860A JP2023542860A JP2024504632A5 JP 2024504632 A5 JP2024504632 A5 JP 2024504632A5 JP 2023542860 A JP2023542860 A JP 2023542860A JP 2023542860 A JP2023542860 A JP 2023542860A JP 2024504632 A5 JP2024504632 A5 JP 2024504632A5
- Authority
- JP
- Japan
- Prior art keywords
- sigma
- compound
- nash
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163137915P | 2021-01-15 | 2021-01-15 | |
| US63/137,915 | 2021-01-15 | ||
| PCT/US2022/012516 WO2022155471A1 (en) | 2021-01-15 | 2022-01-14 | Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504632A JP2024504632A (ja) | 2024-02-01 |
| JP2024504632A5 true JP2024504632A5 (https=) | 2025-01-17 |
Family
ID=82448695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023542860A Pending JP2024504632A (ja) | 2021-01-15 | 2022-01-14 | 非アルコール性脂肪肝疾患および関連する疾患または障害を処置または改善するための化合物、組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240307325A1 (https=) |
| EP (1) | EP4277898A4 (https=) |
| JP (1) | JP2024504632A (https=) |
| KR (1) | KR20230148156A (https=) |
| CA (1) | CA3204756A1 (https=) |
| WO (1) | WO2022155471A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116942821A (zh) * | 2023-06-02 | 2023-10-27 | 深圳市第二人民医院(深圳市转化医学研究院) | Sigmar1基因抑制剂在制备治疗或预防脂肪肝病的药物中的应用 |
| WO2025194019A1 (en) * | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Methods for treating liver fibrosis and non-alcoholic fatty liver disease |
| WO2026057679A1 (en) * | 2024-09-11 | 2026-03-19 | Institut National de la Santé et de la Recherche Médicale | Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130142861A1 (en) * | 2011-12-05 | 2013-06-06 | National Yang Ming University | Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis |
| WO2014015157A2 (en) * | 2012-07-19 | 2014-01-23 | Philadelphia Health & Education Corporation | Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
| WO2018112122A1 (en) * | 2016-12-16 | 2018-06-21 | Drexel University | Methods of identifying and treating tumors with sigma1 inhibitors |
| EP3745862B1 (en) * | 2018-01-31 | 2024-06-26 | Mayo Foundation for Medical Education and Research | D1 dopamine receptor agonists for treating fibrotic pathologies |
| WO2020112846A1 (en) * | 2018-11-27 | 2020-06-04 | Northwestern University | Small molecule modulators of sigma-1 and sigma-2 receptors and uses thereof |
-
2022
- 2022-01-14 CA CA3204756A patent/CA3204756A1/en active Pending
- 2022-01-14 US US18/272,486 patent/US20240307325A1/en active Pending
- 2022-01-14 WO PCT/US2022/012516 patent/WO2022155471A1/en not_active Ceased
- 2022-01-14 KR KR1020237027597A patent/KR20230148156A/ko active Pending
- 2022-01-14 JP JP2023542860A patent/JP2024504632A/ja active Pending
- 2022-01-14 EP EP22740146.0A patent/EP4277898A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024504632A5 (https=) | ||
| JP7005551B2 (ja) | メラノーマの処置および診断 | |
| US12291494B2 (en) | Methods of treating fibrosis | |
| TW201639571A (zh) | 非酒精性脂肪肝病以及/或脂質營養不良症之治療方法 | |
| PT2260101E (pt) | Microrna (mirna) e alvos a jusante para propósitos de diagnóstico e terapêuticos | |
| CA2889892A1 (en) | Alternative uses for hbv assembly effectors | |
| KR101996245B1 (ko) | 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물 | |
| JP2024510787A (ja) | ポリヌクレオチド組成物、関連製剤、およびその使用方法 | |
| WO2016043849A2 (en) | Compounds for treating acute respiratory distress syndrome or a negative effect thereof | |
| US20250101428A1 (en) | Modification patterns for small interfering rna molecules with high stability and gene silencing activities | |
| US20240307325A1 (en) | Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders | |
| JP2023526567A (ja) | バルドキソロンメチルまたはそのアナログを用いてｃｏｖｉｄ－１９を処置する方法 | |
| JP2024519056A (ja) | 膵疾患及び肝疾患を治療するための方法及び組成物 | |
| US11903912B2 (en) | Composition for preventing and treating breast cancer including selenopsammaplin A as active ingredients | |
| RU2762280C2 (ru) | Новое лекарственное средство для лечения неалкогольного стеатогепатита и фиброза | |
| TWI906348B (zh) | 脂肪性肝疾病之治療劑 | |
| CN109136224B (zh) | miR-221/222及其抑制剂用于制备调控肝脂肪沉积、肝纤维化和肝细胞癌的药物 | |
| US20230332158A1 (en) | Novel use of hic-5 inhibitor | |
| JP2025512445A5 (https=) | ||
| KR20250032905A (ko) | Tm4sf5-특이적 억제제로서의 신규한 이소옥사졸 화합물 및 이의 용도 | |
| RU2021119212A (ru) | Соли четвертичного аммония в качестве ингибиторов продуцирования триметиламина | |
| HK1156360A (en) | Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes |